Aim-To study cerebrospinal fluid (CSF) activity of tissue plasminogen activator (tPA) in patients with neurological diseases.
plasminogen activators.
Plasminogen activators, tissue-type (tPA) and urokinase-type (uPA), are serine proteases, the most well characterised function of which is the conversion of the inactive zymogen plasminogen into the active protease plasmin. Plasminogen activators have been implicated in a number of biological processes, including fibrinolysis and thrombolysis, cell migration, tissue invasion by both normal and malignant cells, and tissue remodelling.' 2 Altered plasminogen activation has been reported in patients with diabetes3 4 and rheumatoid arthritis.' The latter study also recorded raised plasmin concentrations in synovial fluid.'
Similarly, high plasma plasminogen activator concentrations have been observed in patients with acute non-lymphoblastic leukaemia. 6 
ZYMOGRAPHY
Zymography was used for the qualitative detection of plasminogen activator activity in CSF. Briefly, samples were run on an 8% polyacrylamide gel in the presence of SDS under non-reducing conditions.2' The molecular weights of the lysed bands were estimated by comparison with pre-stained low molecular weight marker proteins (Pharmacia, Uppsala, Sweden). Activity standards of uPA (Calbiochem, La Jolla, California, USA) and tPA (American Diagnostica, Greenwich, Connecticut, USA) were also included. Before zymography, SDS was removed by washing the gel for six hours with phosphate buffered saline (PBS), pH 7.4, containing 2.5% Triton X-100. An agarose gel containing casein and 1.7 jg/ml plasminogen was then placed over the polyacrylamide gel, and the overlay incubated for 24-48 hours at 37°C in a humidified chamber. To characterise the protease present further, 10 ,ug/ml of an anticatalytic monoclonal antibody directed against uPA (catalogue number 394; American Diagnostica) was added to the polyacrylamide gel before incubation with the casein-agarose gel.
IMMUNOCAPTURE ASSAY FOR tPA AND UPA
The uPA and tPA activities of CSF were measured by an immunocapture assay as reported previously.22 23 Pro-uPA was activated by the addition of purified human plasminogen containing traces of plasmin. Thus, PAI-1 and pro-uPA can be present together in the sample without interference. tPA was assayed by a slightly modified procedure using 20 was allowed to proceed for 45 minutes at 37°C and the plasmin produced was assayed by its thioesterase activity.25 To estimate the amount of enzyme produced, high molecular weight two-chain uPA (80 000 IU/mg; American Diagnostica) and two-chain tPA (650 000 IU/mg; American Diagnostica) were used as standards.
STATISTICS
Results are reported as mean (SEM). The Student's t test was used for the comparison of means. Correlation coefficients were evaluated according to Pearson. Results were considered significant when p < 0.05.
Results
Samples were qualitatively screened for both uPA and tPA activity by zymography and positive samples were quantitated by the immunocapture assay. Positive samples were seen as lytic bands of tPA at molecular weight of 70 kilodaltons and uPA at molecular weight of 50 kilodaltons (data not shown). We observed significantly higher mean tPA activities in patients with multiple sclerosis (p < 0.0001), leukaemia (p < 0.001) and encephalitis (p < 0.0001) in comparison with the reference subjects (table 1) .
In contrast, there were no statistically significant differences in the mean activities of tPA in patients with meningitis, facial paresis and polyradiculitis when compared with the reference subjects (table 1) . The mean tPA activity in patients with multiple sclerosis was very increased compared with the mean activities in each of the other patient groups. The mean activity in patients with leukaemia was higher than the mean activities in those with meningitis and polyradiculitis, but not in those with encephalitis and facial paresis.
The CSF tPA activity correlated positively with age in the reference subjects (r = 0.52; p = 0.018). No correlation was observed in patients with leukaemia, encephalitis and multiple sclerosis.
Some of the samples had quantifiable levels of uPA activity: three of seven samples from patients with multiple sclerosis, 10 of 21 from those with encephalitis and five of nine from patients with leukaemia. The highest activities were recorded in patients with leukaemia (table 1). Discussion tPA activity in patients with multiple sclerosis was raised consistently and was significantly higher than in any of the other groups studied.
Multiple sclerosis is a chronic disease of the central nervous system of largely unknown aetiology, affecting young and middle aged adults. The myelin sheaths surrounding nerves in the brain and spinal cord are damaged, which affects the function of the nerves involved. The disease affects different parts of the brain and spinal cord, resulting in typically scattered symptoms. The involvement of plasminogen activator induction in the pathogenesis of multiple sclerosis and encephalitis has been suggested by studies of peripheral blood lymphocytes. 26 The authors also reported the disappearance of plasminogen activator induction in association with resolution of neurological symptoms. 26 It is also worth considering activation of the vascular endothelium, as this is thought to have an important role in the pathogenesis of inflammation, thrombosis and vasculitis. En In contrast, the tPA activities observed in patients with meningitis, facial paresis and polyradiculitis were very similar to those observed in the reference subjects. The CSF tPA activity correlated positively with age in the reference subjects; no correlation was observed in any of the other groups. The tPA activity also correlated negatively with the interval between sample collection and analysis; samples were stable for up to 10 days when stored frozen. This was not the case for uPA, which may be the result of the very low levels of uPA activity detected in these samples. Further studies involving CSF are required to elucidate the role of plasminogen activators in the diagnosis and pathogenesis of the above clinical conditions, especially in multiple sclerosis, leukaemia and encephalitis, and possibly also in facial paresis. There will also be the need to study PAI-1 in the CSF of these patients, in comparison with concentrations present in CSF of normal subjects.37 
